In women, palbociclib improves progression-free survival in ER+, HER-2– breast cancer when combined with an aromatase inhibitor (letrozole) or an ER downregulator (fulvestrant), so it received approval from the FDA and EMA (194). This evidence concerns the gene CYP19A1 and breast carcinoma.